Document Detail

A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
MedLine Citation:
PMID:  19585824     Owner:  NLM     Status:  MEDLINE    
Dexrabeprazole [R(+) rabeprazole] is a novel proton-pump inhibitor which has recently become available in India for the treatment of acid peptic diseases. Experimental and clinical studies have shown superiority of dexrabeprazole (at half the recommended rabeprazole dose) over rabeprazole in terms of favourable pharmacokinetics, better efficacy and faster and greater healing activity. Results of present study in a large population of 4931 patients of acid peptic disorders, reconfirmed safety and efficacy of dexrabeprazole 10 mg once daily in the treatment of gastro-oesophageal reflux disease and also showed its effectiveness in the treatment of patients with peptic ulcers (gastric/duodenal).
S C Jain;
Related Documents :
18641054 - Pulmonary histopathology in an experimental model of chronic aspiration is independent ...
6417314 - Studies on pharmacological activation of human serum igg by chemical modification and a...
1600044 - Sucralfate diminishes basal acid output without affecting gastrin, h. pylori or gastrit...
6729664 - Prepyloric gastric ulceration.
1704004 - Identification, characterization, and spatial localization of two flagellin species in ...
3081034 - Coenzyme a-mediated transacylation of sn-2 fatty acids from phosphatidylcholine in rat ...
Publication Detail:
Type:  Clinical Trial, Phase IV; Journal Article    
Journal Detail:
Title:  Journal of the Indian Medical Association     Volume:  107     ISSN:  0019-5847     ISO Abbreviation:  J Indian Med Assoc     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-07-09     Completed Date:  2009-08-20     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  7505608     Medline TA:  J Indian Med Assoc     Country:  India    
Other Details:
Languages:  eng     Pagination:  111-3     Citation Subset:  IM    
Digestive Endoscopy Clinic and A Day Care Center, Pune 411011.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects,  therapeutic use*
Anti-Ulcer Agents / adverse effects,  therapeutic use*
Gastroesophageal Reflux / drug therapy*
Middle Aged
Peptic Ulcer / drug therapy*
Product Surveillance, Postmarketing
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 32828355LL/rabeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ewing's sarcoma/ primitive neuro-ectoclermal tumour: a case report.
Next Document:  Compiled report on clinical efficacy and safety of nifedipine retard 10/20/nifedipine CD 30, as a fi...